NewCardio Inc. (NWCI)
OTC PINK OTC PINK Primary Summary
NewCardio Inc. (NWCI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NewCardio Inc. ever had a stock split?
NewCardio Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Jess Emery Jones CEO | OTC PINK Exchange | 65106G100 CUSIP |
| US Country | 10 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
NewCardio, Inc. is a cardiac diagnostic and services company with a primary focus on the development and commercialization of innovative software platform technology solutions. These solutions are designed for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as for the cardiac safety assessment of drugs under development. The company leverages advanced technology to provide real-time and 3-D analysis of the heart's electrical activity by utilizing standard 12-lead electrocardiogram (ECG) electrodes. Founded in 2004 and headquartered in Branchburg, New Jersey, NewCardio is dedicated to advancing cardiac care and improving patient outcomes through its sophisticated technology platforms.
Products and Services
- QTinno
- CardioBip
- my3KG
QTinno stands as an automated cardiac safety solution developed by NewCardio. It aims at replacing traditional manual and semi-automated methodologies with sophisticated algorithms designed to automatically measure, analyze, and report on the ECGs collected. This technology is particularly vital for the cardiac safety assessment of new drugs, offering a more efficient, accurate, and streamlined approach to ECG analysis.
CardioBip represents a mobile ECG transtelephonic system that encompasses a compact ECG recording and transmitting device paired with Web-enabled software. This software is tasked with receiving, processing, and analyzing the transmitted data. The system offers a convenient and efficient solution for real-time ECG monitoring and analysis, promoting enhanced cardiac care and monitoring outside traditional clinical settings.
The my3KG software application is another innovative development by NewCardio. It provides a unique method for assessing cardiac electrical activity both temporally and spatially. By offering real-time and 3-D analysis capabilities, my3KG enhances the accuracy and comprehensiveness of cardiac assessments, potentially transforming the way cardiac conditions are diagnosed and monitored.
